Drug-Drug Interactions (DDI) Archives

Blog

Replacing Traditional TQT Studies with Model-Based Concentration-QTc (C-QTc) Analysis for Cardiovascular Safety in Drug Development

Learn how our experts use concentration-QTc (C-QTc) analysis to replace costly TQT studies, streamline QT…

CertaraAugust 6, 2025

Webinar

De-risking DDI Management during Clinical Trials: Introducing DIDB’s Concomitant Meds Navigator

CertaraAugust 5, 2025

Press Release

Certara Simcyp® Simulator Becomes First and Only Software Platform to Receive EMA Qualification Opinion for PBPK Modeling

Certara announces that EMA has formally qualified the Simcyp® Simulator for use in regulatory submissions…

CertaraAugust 4, 2025

Conference

EACPT 2025 CONGRESS

- - Booth

Danielle PillsburyJune 10, 2025

Blog

What are the most common in vitro drug-drug interaction study gaps?

Certara drug interaction science experts share data and experimental design gaps commonly found in in…

CertaraJune 9, 2025

On-Demand Webinar

Clinical and Physiologically Based Pharmacokinetic Model Evaluations of Adagrasib Drug–Drug Interactions

Director, Clinical Pharmacology, ORIC Pharmaceuticals SVP, Head of Simcyp PBPK Modeling Services, Certara Director, PBPK…

CertaraApril 21, 2025

Blog

Measuring metabolites in index clinical DDI studies

February 7, 2025A key drug development safety consideration is whether the drug candidate will interact…

CertaraFebruary 7, 2025

On-Demand Webinar

Optimizing DDI Knowledge throughout Drug Development

Lorem ipsum dolor sit amet consectetur. Donec diam risus volutpat tempor. Massa accumsan aliquam nibh…

CertaraJanuary 6, 2025

Publication

Static Versus Dynamic Model Predictions of Competitive Inhibitory Metabolic Drug–Drug Interactions via Cytochromes P450: One Step Forward and Two Steps Backwards

Predicting metabolic drug–drug interactions (DDIs) via cytochrome P450 enzymes (CYP) is essential in drug development,…

CertaraDecember 12, 2024

Publication

Medicines in pregnancy: A clinical pharmacology extrapolation framework to address knowledge gaps

CertaraOctober 16, 2024

Drug-Drug Interactions (DDI)

Replacing Traditional TQT Studies with Model-Based Concentration-QTc (C-QTc) Analysis for Cardiovascular Safety in Drug Development

De-risking DDI Management during Clinical Trials: Introducing DIDB’s Concomitant Meds Navigator

Certara Simcyp® Simulator Becomes First and Only Software Platform to Receive EMA Qualification Opinion for PBPK Modeling

EACPT 2025 CONGRESS

What are the most common in vitro drug-drug interaction study gaps?

Clinical and Physiologically Based Pharmacokinetic Model Evaluations of Adagrasib Drug–Drug Interactions

Measuring metabolites in index clinical DDI studies

Optimizing DDI Knowledge throughout Drug Development

Static Versus Dynamic Model Predictions of Competitive Inhibitory Metabolic Drug–Drug Interactions via Cytochromes P450: One Step Forward and Two Steps Backwards

Medicines in pregnancy: A clinical pharmacology extrapolation framework to address knowledge gaps

Newsletter sign up

Quick links

Solutions

Contact